Suboxone.com - Qualification

The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "View PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

You are leaving Suboxone.com. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals. You are solely responsible for your interactions with such websites.

Links are provided as a public service and for informational purposes only.

You are leaving Suboxone.com and are being redirected to HereToHelpProgram.com, the website that contains the information you requested. HereToHelpProgram.com and Suboxone.com are owned and operated by Reckitt Benckiser Pharmaceuticals Inc.

As always, your information will not be sold or shared with anyone. See our privacy policy for more information.

IMPORTANT INFORMATION:

On December 8, 2006, Federal legislation was passed allowing physicians to treat up to 100 opioid-dependent patients with Suboxone at any given time—a significant increase from the previous limit of 30 patients.

There may be doctors in your area participating in a study to measure opioid dependence treatment outcomes. Patients who meet the eligibility requirements to participate in this study can receive up to $225 in compensation to complete surveys about their treatment.

NOTE: This study is only open to patients not currently under the care of a physician for opioid dependence and are seeking a treatment provider.

Please call 1-866-455-8876 between 9:00 AM to 7:30 PM EST to get more information.

Seeking Information for myself or loved one

Here to Help™ provides support throughout treatment. Whether you're seeking treatment information or you're already in treatment, we can provide resources that can help you make treatment a success.

HereToHelpProgram.com respects your privacy.
Read our Privacy Policy for more information.

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this website has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Prescribing Information -- Site Map

Support That Helps Patients Stay In Treatment

Learn how patients can benefit from this free support system

Become a Here to Help Provider

Learn how becoming a provider can benefit you and your practice

Qualifications

According to DATA 2000, licensed physicians are considered qualified to prescribe SUBOXONE if at least 1 of the following criteria has been met:

Holds an addiction psychiatry subspecialty board certification from the American Board of Medical Specialties
Holds an addiction medicine certification from the American Society of Addiction Medicine (ASAM)
Holds an addiction medicine subspecialty board certification from the American Osteopathic Association (AOA)
Completion of not less than 8 hours of authorized training on the treatment or management of opioid-dependent patients

Organizations currently authorized to provide training:
American Academy of Addiction Psychiatry (AAAP), American Medical Association, AOA (through the American Osteopathic Academy of Addiction Medicine [AOAAM]), American Psychiatric Association (APA), and ASAM

Participation as an investigator in 1 or more clinical trials leading to the approval of SUBOXONE
Training or other such experience as determined by the physician's state medical licensing board
Training or other such experience as determined by the United States Secretary of Health and Human Services

In addition, physicians must satisfy BOTH of the following criteria:

Have the capacity to provide or to refer patients for necessary ancillary services, such as psychosocial therapy
Agree to treat no more than 30 patients at any one time in an individual or group practice during the first year following certification or 100 patients upon re-notification of the need and intent to treat up to 100 patients after one year

All of the above, including certification qualifications and training criteria, is described in more detail in the full text of DATA 2000.

Buprenorphine Training
SAMHSA encourages all physicians who are interested in treating opioid dependence—including those who already meet one or more of the qualifying criteria listed above—to participate in a DATA 2000 certification program before prescribing SUBOXONE.

Information about training courses may be found on the websites of the organizations listed below, or by contacting the organization directly:

American Academy of Addiction Psychiatry (AAAP)
Phone: (401) 524-3076
Contact: www.aaap.org/contact.htm
Website: www.aaap.org

American Osteopathic Academy of Addiction Medicine (AOAAM)
Phone: (800) 621-1773
Website: www.aoaam.org

American Psychiatric Association (APA)
Phone: (703) 907-7300
E-mail: apa@psych.org
Website: www.psych.org

American Society of Addiction Medicine (ASAM)
Phone: (301) 656-3920
E-mail: email@asam.org
Website: www.asam.org

Home -- About SUBOXONE -- Here to Help -- Treatment -- Certification -- Pharmacists -- Counselors -- Nurses -- Resources

SUBOXONE^®, SUBUTEX^®, and Here to Help^® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.

Important Safety Information

SUBOXONE^® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence.

It is extremely dangerous to self-administer non-prescribed benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE.

SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists.

Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine.

Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine.

There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy.

Caution should be exercised when driving cars or operating machinery.

Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately.

The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and sweating (14%, placebo 10%). Please see full Prescribing Information for a complete list.

To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information